XPRIZE Chairman Peter Diamandis stated that US healthcare spending accounts for 18% of the gross domestic product (GDP), totaling $5.3 trillion, or $15,474 per person. He advocates for a shift from treatment after illness to prevention.

This set of figures aligns with the 2024 National Health Expenditure Accounts from the Centers for Medicare & Medicaid Services. The account records a 7.2% increase in spending for 2024, reaching $5.3 trillion, or $15,474 per person, which constitutes 18.0% of GDP; the percentage was 17.7% in 2023 and 17.6% in 2022. The per capita spending was $14,580 the previous year.

In terms of categories, private insurance grew by 8.8% to $1.6446 trillion, accounting for 31%. Medicare increased by 7.8% to $1.118 trillion, making up 21%. Medicaid rose by 6.6% to $931.7 billion, representing 18%. Out-of-pocket spending grew by 5.9% to $556.6 billion, accounting for 11%. Hospital spending increased by 8.9% to $1.6347 trillion. Physician and clinical services grew by 8.1% to $1.1097 trillion. Prescription drugs rose by 7.9% to $467 billion. The federal government covers 31% of total spending, households 28%, private businesses 18%, and state and local governments 16%.

The actuary's office stated that the growth rate for 2024 is primarily driven by utilization and more complex services, with prices being a factor but not the main cause. GDP is projected to grow by 5.3% in the same year, with healthcare spending growth outpacing the economy. Official projections estimate an average annual healthcare spending increase of 5.4% from 2025 to 2034, with GDP growing at an average of 4.1%, and the percentage rising to 20.6% by 2034.

Diamandis did not provide figures on how much could be saved through prevention in this post, nor did he mention new clinical trials. He previously wrote in August that trillions are spent on end-of-life treatments, with almost no investment in early and mid-stage prevention. His company, Fountain Life, which he co-founded and chairs, offers annual imaging, genetic, and blood tests aimed at predicting and detecting diseases early.

This is not a grant. The buyers are the federal government, households, and businesses that continue to pay for treatment; the sellers are membership clinics that treat preventive testing as an alternative entry point. The event is driven by a set of official numbers being reiterated, with money already accounted for in the $5.3 trillion. The beneficiaries are hospitals, clinical services, and private insurance, which are the largest categories; the pressure is on the same institutions that would see reduced utilization if budgets were truly shifted from end-of-life treatment. The post does not change payment rules.

Source: Public Information